P2X7 purinergic receptor: A potential target in heart diseases (Review)

Bin Dayel,Anfal F.; Alonazi,Asma S.; Alshammari,Tahani K.; Alrasheed,Nouf M.

doi:10.3892/mmr.2023.12961

P2X7 purinergic receptor: A potential target in heart diseases (Review)

Authors:
- Anfal F. Bin Dayel
- Asma S. Alonazi
- Tahani K. Alshammari
- Nouf M. Alrasheed
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, 12371 Riyadh, Kingdom of Saudi Arabia
Published online on: February 15, 2023 https://doi.org/10.3892/mmr.2023.12961
Article Number: 74

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The P2X7 purinergic receptor (P2X7R) is a non‑selective cation channel activated by high levels of adenosine triphosphate that are commonly present in serious conditions. Activation of this purinergic receptor is closely related to the development of various disease states including inflammatory and neurodegenerative disorders, orthopedic diseases and types of cancer. Accumulating evidence has shown that the P2X7R plays a crucial role in the development of various heart diseases. For example, activation of P2X7Rs may alleviate myocardial ischemia‑reperfusion injury by releasing endogenous cardiac protective substances. In contrast to these findings, activation of P2X7Rs can promote the development of acute myocardial infarction and myocarditis by inducing inflammatory responses. Activation of these receptors can also contribute to the development of different types of cardiomyopathies including diabetic cardiomyopathy, dilated cardiomyopathy and hypertrophic cardiomyopathy by inducing cardiac hypertrophy, fibrosis and apoptosis. Notably, inhibition of P2X7Rs can improve cardiac structure and function abnormalities following acute myocardial infarction, reduction of inflammatory responses following myocarditis and attenuation of the cardiomyopathy process. Furthermore, recent evidence has demonstrated that P2X7Rs are highly active in patients infected with coronavirus disease‑2019 (COVID‑19). Hyperactivation of P2X7Rs in COVID‑19 may induce severe myocardial injury through the activation of several signaling pathways. The present study reviewed the important role of the P2X7R in cardiac dysfunctions and discusses its use as a possible new therapeutic approach for the prevention and treatment of several myocardial diseases.

View Figures

View References

1	WHO, . Cardiovascular Diseases (CVDs). Fact sheet. WHO; Geneva: 2021
2	Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI
3	Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H and Hashimoto M: P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz). 58:91–96. 2010. View Article : Google Scholar : PubMed/NCBI
4	Zhang WJ, Zhu ZM and Liu ZX: The role and pharmacological properties of the P2X7 receptor in neuropathic pain. Brain Res Bull. 155:19–28. 2020. View Article : Google Scholar : PubMed/NCBI
5	Alves LA, Bezerra RJS, Faria RX, Ferreira LG and da Silva Frutuoso V: Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules. 18:10953–10972. 2013. View Article : Google Scholar : PubMed/NCBI
6	Li Q, Zhu X, Song W, Peng X and Zhao R: The P2X7 purinergic receptor: A potential therapeutic target for lung cancer. J Cancer Res Clin Oncol. 146:2731–2741. 2020. View Article : Google Scholar : PubMed/NCBI
7	Yang C, Shi S, Su Y, Tong JS and Li L: P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-κB signalling pathway in colorectal cancer cells. J Cell Mol Med. 24:10830–10841. 2020. View Article : Google Scholar : PubMed/NCBI
8	Giannuzzo A, Saccomano M, Napp J, Ellegaard M, Alves F and Novak I: Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int J Cancer Res. 139:2540–2552. 2016. View Article : Google Scholar : PubMed/NCBI
9	Huang H, He YM, Lin MM, Wang Y, Zhang X, Liang L and He X: P2X7Rs: New therapeutic targets for osteoporosis. Purinergic Signal. Feb 2–2022.(Epub ahead of print). View Article : Google Scholar
10	Grygorowicz T, Strużyńska L, Sulkowski G, Chalimoniuk M and Sulejczak D: Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis. Neurochem Int. 57:823–829. 2010. View Article : Google Scholar : PubMed/NCBI
11	Vessey DA, Li L and Kelley M: Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre-and postconditioning. J Cardiovasc Pharmacol Ther. 15:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zempo H, Sugita Y, Ogawa M, Watanabe R, Suzuki J and Isobe M: A P2X7 receptor antagonist attenuates experimental autoimmune myocarditis via suppressed myocardial CD4+ T and macrophage infiltration and NADPH oxidase 2/4 expression in mice. Heart Vessels. 30:527–533. 2015. View Article : Google Scholar : PubMed/NCBI
13	Gao H, Yin J, Shi Y, Hu H, Li X, Xue M, Cheng W, Wang Y, Li X, Li Y, et al: Targeted P2X7R shRNA delivery attenuates sympathetic nerve sprouting and ameliorates cardiac dysfunction in rats with myocardial infarction. Cardiovasc Ther. 35:2017. View Article : Google Scholar
14	Dos Anjos F, Simões JLB, Assmann CE, Carvalho FB and Bagatini MD: Potential therapeutic role of purinergic receptors in cardiovascular disease mediated by SARS-CoV-2. J Immunol Res. 2020:86320482020. View Article : Google Scholar : PubMed/NCBI
15	Di Virgilio F, Tang Y, Sarti AC and Rossato M: A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Br J Pharmacol. 177:4990–4994. 2020. View Article : Google Scholar : PubMed/NCBI
16	Batista Simões JL, Sobierai LD, Pereira SM, Rodrigues dos Santos MV and Bagatini MD: Therapeutic potential of P2X7 purinergic receptor modulation in the main organs affected by the COVID-19 Cytokine Storm. Curr Pharm Des. 28:1798–1814. 2022. View Article : Google Scholar : PubMed/NCBI
17	Burnstock G: A basis for distinguishing two types of purinergic receptor. Cell Membrane Receptors for Drugs and Hormone: A Multidisciplinary Approach. 107–118. 1978.
18	Burnstock G and Kennedy C: Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 16:433–440. 1985. View Article : Google Scholar : PubMed/NCBI
19	Abbracchio MP and Burnstock G: Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacol Ther. 64:445–475. 1994. View Article : Google Scholar : PubMed/NCBI
20	North RA: Molecular physiology of P2X receptors. Physiol Rev. 82:1013–1067. 2002. View Article : Google Scholar : PubMed/NCBI
21	Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA and Weisman GA: International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 58:281–341. 2006. View Article : Google Scholar : PubMed/NCBI
22	Burnstock G and Verkhratsky A: Receptors for purines and pyrimidines. Springer Berlin; Heidelberg: 2012, View Article : Google Scholar
23	Bodin P and Burnstock G: Purinergic signalling: ATP release. Neurochem Res. 26:959–969. 2001. View Article : Google Scholar : PubMed/NCBI
24	Dosch M, Gerber J, Jebbawi F and Beldi G: Mechanisms of ATP release by inflammatory cells. Int J Mol Sci. 19:12222018. View Article : Google Scholar : PubMed/NCBI
25	Sawada K, Echigo N, Juge N, Miyaji T, Otsuka M, Omote H, Yamamoto A and Moriyama Y: Identification of a vesicular nucleotide transporter. Proc Natl Acad Sci USA. 105:5683–5686. 2008. View Article : Google Scholar : PubMed/NCBI
26	Junger WG: Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 11:201–212. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xiong Y, Sun S, Teng S, Jin M and Zhou Z: Ca²⁺-dependent and Ca²⁺-independent ATP release in astrocytes. Front Mol Neurosci. 11:2242018. View Article : Google Scholar : PubMed/NCBI
28	Abbracchio MP, Burnstock G, Verkhratsky A and Zimmermann H: Purinergic signalling in the nervous system: An overview. Trends Neurosci. 32:19–29. 2009. View Article : Google Scholar : PubMed/NCBI
29	Kuzmin AI, Lakomkin VL, Kapelko VI and Vassort G: Interstitial ATP level and degradation in control and postmyocardial infarcted rats. Am J Physiol. 275:C766–C771. 1998. View Article : Google Scholar : PubMed/NCBI
30	Jiang LH, Baldwin JM, Roger S and Baldwin SA: Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol. 4:552013. View Article : Google Scholar : PubMed/NCBI
31	Burnstock G and Kennedy C: P2X receptors in health and disease. Adv Pharmacol. 61:333–372. 2011. View Article : Google Scholar : PubMed/NCBI
32	Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E and Di Virgilio F: The P2X7 receptor: A main player in inflammation. Biochem Pharmacol. 151:234–244. 2018. View Article : Google Scholar : PubMed/NCBI
33	Andrejew R, Oliveira-Giacomelli Á, Ribeiro DE, Glaser T, Arnaud-Sampaio VF, Lameu C and Ulrich H: The P2X7 receptor: Central hub of brain diseases. Front Mol Neurosci. 13:1242020. View Article : Google Scholar : PubMed/NCBI
34	Virginio C, MacKenzie A, Rassendren FA, North RA and Surprenant A: Pore dilation of neuronal P2X receptor channels. Nat Neurosci. 2:315–321. 1999. View Article : Google Scholar : PubMed/NCBI
35	Wiley JS, Sluyter R, Gu BJ, Stokes L and Fuller SJ: The human P2X7 receptor and its role in innate immunity. Tissue Antigens. 78:321–332. 2011. View Article : Google Scholar : PubMed/NCBI
36	Alves LA, de Melo Reis RA, de Souza CA, de Freitas MS, Teixeira PC, Neto Moreira Ferreira D and Xavier RF: The P2X7 receptor: Shifting from a low-to a high-conductance channel-an enigmatic phenomenon? Biochim Biophys Acta. 1838:2578–2587. 2014. View Article : Google Scholar : PubMed/NCBI
37	Bartlett R, Stokes L and Sluyter R: The P2X7 receptor channel: Recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 66:638–675. 2014. View Article : Google Scholar : PubMed/NCBI
38	Artlett CM: The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J. 6:80–86. 2012. View Article : Google Scholar : PubMed/NCBI
39	Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H and Lieberman J: Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 535:153–158. 2016. View Article : Google Scholar : PubMed/NCBI
40	Ferrari D, Wesselborg S, Bauer MK and Schulze-Osthoff K: Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65 (RelA). J Cell Biol. 139:1635–1643. 1997. View Article : Google Scholar : PubMed/NCBI
41	Ferrari D, Stroh C and Schulze-Osthoff K: P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 274:13205–13210. 1999. View Article : Google Scholar : PubMed/NCBI
42	Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA and Junger WG: Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 23:1685–1693. 2009. View Article : Google Scholar : PubMed/NCBI
43	Zhang Y, Cheng H, Li W, Wu H and Yang Y: Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. Int J Cancer. 145:1068–1082. 2019. View Article : Google Scholar : PubMed/NCBI
44	Langhner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HEER2 (neu) signaling increase the rate of hypoxia inducible factor 1-alpha (HIF-1-alpha) synthesis: Novel mechanism for HIF-mediated vascular endothelial growth factor expression. Mol Cell Bioi. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
45	Amoroso F, Capece M, Rotondo A, Cangelosi D, Ferracin M, Franceschini A, Raffaghello L, Pistoia V, Varesio L and Adinolfi E: The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: Evidence in experimental neuroblastoma. Oncogene. 34:5240–5251. 2015. View Article : Google Scholar : PubMed/NCBI
46	Hill LM, Gavala ML, Lenertz LY and Bertics PJ: Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol. 185:3028–3034. 2010. View Article : Google Scholar : PubMed/NCBI
47	Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T, Rosa R, Indelicato M, Fini M, Pucci B and Russo MA: Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis. 32:1167–1175. 2011. View Article : Google Scholar : PubMed/NCBI
48	Ji Z, Xie Y, Guan Y, Zhang Y, Cho KS, Ji M and You Y: Involvement of P2X7 receptor in proliferation and migration of human glioma cells. Biomed Res Int. 2018:85913972018. View Article : Google Scholar : PubMed/NCBI
49	Bartlett R, Yerbury JJ and Sluyter R: P2X7 receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia. Mediators Inflamm. 2013:2718132013. View Article : Google Scholar : PubMed/NCBI
50	Mazrouei S, Sharifpanah F, Bekhite MM, Figulla HR, Sauer H and Wartenberg M: Cardiomyogenesis of embryonic stem cells upon purinergic receptor activation by ADP and ATP. Purinergic Signal. 11:491–506. 2015. View Article : Google Scholar : PubMed/NCBI
51	Hesse J, Leberling S, Boden E, Friebe D, Schmidt T, Ding Z, Dieterich P, Deussen A, Roderigo C, Rose CR, et al: CD73-derived adenosine and tenascin-C control cytokine production by epicardium-derived cells formed after myocardial infarction. FASEB J. 31:3040–3053. 2017. View Article : Google Scholar : PubMed/NCBI
52	Musa H, Tellez JO, Chandler NJ, Greener ID, Mączewski M, Mackiewicz U, Beresewicz A, Molenaar P, Boyett MR and Dobrzynski H: P2 purinergic receptor mRNA in rat and human sinoatrial node and other heart regions. Naunyn Schmiedebergs Arch Pharmacol. 379:541–549. 2009. View Article : Google Scholar : PubMed/NCBI
53	Barth K, Pfleger C, Linge A, Sim JA, Surprenant A, Steinbronn N, Strasser RH and Kasper M: Increased P2X7R expression in atrial cardiomyocytes of caveolin-1 deficient mice. Histochem. Cell Biol. 134:31–38. 2010.PubMed/NCBI
54	Gentile D, Natale M, Lazzerini PE, Capecchi PL and Laghi-Pasini F: The role of P2X7 receptors in tissue fibrosis: A brief review. Purinergic Signal. 11:435–440. 2015. View Article : Google Scholar : PubMed/NCBI
55	Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons, ; Thygesen K, Alpert JS, et al: Third universal definition of myocardial infarction. J Am Coll Cardiol. 60:1581–1598. 2012. View Article : Google Scholar : PubMed/NCBI
56	Liehn EA, Postea O, Curaj A and Marx N: Repair after myocardial infarction, between fantasy and reality: The role of chemokines. J Am Coll Cardiol. 58:2357–2362. 2011. View Article : Google Scholar : PubMed/NCBI
57	Forte E, Furtado MB and Rosenthal N: The interstitium in cardiac repair: Role of the immune-stromal cell interplay. Nat Rev Cardiol. 15:601–616. 2018. View Article : Google Scholar : PubMed/NCBI
58	Ferrini A, Stevens MM, Sattler S and Rosenthal N: Toward regeneration of the heart: Bioengineering strategies for immunomodulation. Front Cardiovasc Med. 6:262019. View Article : Google Scholar : PubMed/NCBI
59	Yin J, Wang Y, Hu H, Li X, Xue M, Cheng W, Wang Y, Li X, Yang N, Shi Y and Yan S: P2X7 receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1β pathway. J Cell Mol Med. 21:2695–2710. 2017. View Article : Google Scholar : PubMed/NCBI
60	Cheng W, Sun Y, Wu Q, Ooi K, Feng Y, Xia C and Zhu D: Paraventricular nucleus P2X7 receptors aggravate acute myocardial infarction injury via ROS-induced vasopressin-V1b activation in rats. Neurosci Bull. 37:641–656. 2021. View Article : Google Scholar : PubMed/NCBI
61	Shi XX, Zheng KC, Shan PR, Zhang L, Wu SJ and Huang ZQ: Elevated circulating level of P2X7 receptor is related to severity of coronary artery stenosis and prognosis of acute myocardial infarction. Cardiol J. 28:453–459. 2021. View Article : Google Scholar : PubMed/NCBI
62	Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF and Abbate A: The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 108:19725–19730. 2011. View Article : Google Scholar : PubMed/NCBI
63	Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M and Eckle T: Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Semin Cardiothorac Vasc Anesth. 16:123–132. 2012. View Article : Google Scholar : PubMed/NCBI
64	Gu M, Zheng AB, Jin J, Cui Y, Zhang N, Che ZP, Wang Y, Zhan J and Tu WJ: Cardioprotective effects of genistin in rat myocardial ischemia-reperfusion injury studies by regulation of P2X7/NF-κB pathway. Evid Based Complement Alternat Med. 2016:53812902016. View Article : Google Scholar : PubMed/NCBI
65	Tu G, Zou L, Liu S, Wu B, Lv Q, Wang S, Xue Y, Zhang C, Yi Z, Zhang X, et al: Long noncoding NONRATT021972 siRNA normalized abnormal sympathetic activity mediated by the upregulation of P2X7 receptor in superior cervical ganglia after myocardial ischemia. Purinergic Signal. 12:521–535. 2016. View Article : Google Scholar : PubMed/NCBI
66	Vessey DA, Li L and Kelley M: Ischemic preconditioning requires opening of pannexin-1/P2X7 channels not only during preconditioning but again after index ischemia at full reperfusion. Mol Cell Biochem. 351:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
67	Wang Y: Mitogen-activated protein kinases in heart development and diseases. Circulation. 116:1413–1423. 2007. View Article : Google Scholar : PubMed/NCBI
68	Magnani JW and Dec GW: Myocarditis: Current trends in diagnosis and treatment. Circulation. 113:876–890. 2006. View Article : Google Scholar : PubMed/NCBI
69	Fung G, Luo H, Qiu Y, Yang D and McManus B: Myocarditis. Circ Res. 118:496–514. 2016. View Article : Google Scholar : PubMed/NCBI
70	Amoah BP, Yang H, Zhang P, Su Z and Xu H: Immunopathogenesis of myocarditis: The interplay between cardiac fibroblast cells, dendritic cells, macrophages and CD 4+ T cells. Scand J Immunol. 82:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
71	Martinez CG, Zamith-Miranda D, Da Silva MG, Ribeiro KC, Brandão IT, Silva CL, Diaz BL, Bellio M, Persechini PM and Kurtenbach E: P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: Autoantibody levels, heart functionality and cytokine expression. Sci Rep. 5:169402015. View Article : Google Scholar : PubMed/NCBI
72	Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association, ; et al: Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 113:1807–1816. 2006. View Article : Google Scholar : PubMed/NCBI
73	Eijgenraam TR, Silljé HHW and de Boer RA: Current understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc Med. 30:353–361. 2020. View Article : Google Scholar : PubMed/NCBI
74	Zhou J, Tian G, Quan Y, Li J, Wang X, Wu W, Li M and Liu X: Inhibition of P2X7 purinergic receptor ameliorates cardiac fibrosis by suppressing NLRP3/IL-1β pathway. Oxid Med Cell Longev. 2020:79562742020. View Article : Google Scholar : PubMed/NCBI
75	Huang S, Wang W, Li L, Wang T, Zhao Y, Lin Y, Huang W, Wang Y and Huang Z: P2X7 receptor deficiency ameliorates STZ-induced cardiac damage and remodeling through PKCβ and ERK. Front Cell Dev Biol. 9:6920282021. View Article : Google Scholar : PubMed/NCBI
76	Biswas A, Raza A, Das S, Kapoor M, Jayarajan R, Verma A, Shamsudheen KV, Murry B, Seth S, Bhargava B, et al: Loss of function mutation in the P2X7, a ligand-gated ion channel gene associated with hypertrophic cardiomyopathy. Purinergic Signal. 15:205–210. 2019. View Article : Google Scholar : PubMed/NCBI
77	Whitworth J: COVID-19: A fast evolving pandemic. Trans R Soc Trop Med Hyg. 114:241–248. 2020. View Article : Google Scholar : PubMed/NCBI
78	Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, Cooper LT Jr and Chahal CAA: Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 17:1463–1471. 2020. View Article : Google Scholar : PubMed/NCBI
79	Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y and Han Y: Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 106:1132–1141. 2020. View Article : Google Scholar : PubMed/NCBI
80	Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, et al: COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 116:1666–1687. 2020. View Article : Google Scholar : PubMed/NCBI
81	Ribeiro DE, Oliveira-Giacomelli Á, Glaser T, Arnaud-Sampaio VF, Andrejew R, Dieckmann L, Baranova J, Lameu C, Ratajczak MZ and Ulrich H: Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Mol Psychiatry. 26:1044–1059. 2021. View Article : Google Scholar : PubMed/NCBI
82	Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K and Zhang C: Angiotensin-converting enzyme 2 and angiotensin 1–7: Novel therapeutic targets. Nat Rev Cardiol. 11:413–426. 2014. View Article : Google Scholar : PubMed/NCBI
83	Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 11:16202020. View Article : Google Scholar : PubMed/NCBI
84	Nishiga M, Wang DW, Han Y, Lewis DB and Wu JC: COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat Rev Cardiol. 17:543–558. 2020. View Article : Google Scholar : PubMed/NCBI
85	De Mello WC and Danser AH: Angiotensin II and the heart: On the intracrine renin-angiotensin system. Hypertension. 35:1183–1188. 2000. View Article : Google Scholar : PubMed/NCBI
86	Wernly B and Zhou Z: More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease. Am J Physiol Heart Circ Physiol. 319:H723–H729. 2020. View Article : Google Scholar : PubMed/NCBI
87	Wagner JA and Kelly RB: Topological organization of proteins in an intracellular secretory organelle: The synaptic vesicle. Proc Natl Acad Sci USA. 76:4126–4130. 1979. View Article : Google Scholar : PubMed/NCBI
88	Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN and Dagnelie PC: Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 112:358–404. 2006. View Article : Google Scholar : PubMed/NCBI